Semaglutide linked with reduced need for diuretics in heart failure patients: Study Dr. Kamal Kant Kohli17 May 2024 7:45 PM ISTSemaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms, physical limitations, and body weight in patients...
Semaglutide tied to meaningful weight loss, waist size reduction and CV benefits in non diabetic overweight adults: Study Dr. Kamal Kant Kohli15 May 2024 10:00 AM ISTResearchers have found in latest research that Semaglutide can produce clinically meaningful weight loss and reduce waist size for at...
Biocon Limited signs an exclusive licensing and supply agreement for generic Ozempic (Semaglutide) commercialization in Brazil with Biomm S.A. Ruchika Sharma20 April 2024 10:13 AM ISTBiocon, Biomm S.A. ink pact for diabetes drug Semaglutide commercialization in Brazil
CDSCO Panel Approves Novo Nordisk's Protocol Amendment Proposal for CagriSema Study Dr. Divya Colin9 April 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novo...
Patients taking semaglutide may have higher rate of "altered skin sensations" and alopecia, finds review Medha Baranwal8 April 2024 8:00 AM ISTUSA: A review of 22 articles published in the Journal of the American Academy of Dermatology found that patients taking oral semaglutide had a higher...
CDSCO Panel grants Novo Nordisk's Protocol Amendment Proposal For Antidiabetic Drug Semaglutide study Dr. Divya Colin31 March 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novo...
Novel GCGR/GLP-1R dual agonist survodutide effectively reduces HbA1c and body weight in type 2 diabetes: Phase 2 trial Medha Baranwal18 March 2024 9:45 PM ISTGermany: A recent study published in Diabetologia has shed light on survodutide dose-response effects on body weight and HbA1c reduction, compared...
Semaglutide 1.0 mg tied to 24% reduction in kidney events among people with type 2 diabetes and CKD: FLOW Trial Medha Baranwal12 March 2024 11:30 PM ISTDenmark: Topline results of the FLOW trial showed a 24% reduction in the risk of kidney disease-related events among patients with type 2 diabetes...
FDA approves semaglutide for major heart disease prevention among obese Dr. Kamal Kant Kohli10 March 2024 9:15 PM ISTThe US Food and Drug Administration (FDA) has approved semaglutide (Wegovy) for reducing risk of cardiovascular death, heart attack, and stroke in...
Working with several countries authorities to tackle counterfeit versions of Ozempic: Novo Nordisk CEO Ruchika Sharma10 March 2024 12:15 PM ISTDenmark: Novo Nordisk's CEO on Friday said the company was working with authorities in several countries to tackle counterfeit versions of its popular...
Semaglutide effective for weight loss and improving glycemic control in type 1 diabetes: Study Medha Baranwal9 March 2024 11:15 AM ISTUSA: A recent pilot real-world study published in Diabetes Technology & Therapeutics has shown the effectiveness of semaglutide in...
Semaglutide reduces severity of common liver disease in people with HIV, reveals study Dr. Kamal Kant Kohli8 March 2024 7:30 PM ISTA weekly injection of semaglutide was safe and reduced the amount of fat in the liver by 31% in people with HIV and metabolic dysfunction-associated...
